Loading…

Blood reference materials from macaques infected with variant Creutzfeldt-Jakob disease agent

Background Variant Creutzfeldt‐Jakob disease (vCJD) is a fatal neurodegenerative infection that can be transmitted by blood and blood products from donors in the latent phase of the disease. Currently, there is no validated antemortem vCJD blood screening test. Several blood tests are under developm...

Full description

Saved in:
Bibliographic Details
Published in:Transfusion (Philadelphia, Pa.) Pa.), 2015-02, Vol.55 (2), p.405-412
Main Authors: McDowell, Kristy L., Nag, Nabanita, Franco, Zulmarie, Bu, Ming, Piccardo, Pedro, Cervenak, Juraj, Deslys, Jean-Philippe, Comoy, Emmanuel, Asher, David M., Gregori, Luisa
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Variant Creutzfeldt‐Jakob disease (vCJD) is a fatal neurodegenerative infection that can be transmitted by blood and blood products from donors in the latent phase of the disease. Currently, there is no validated antemortem vCJD blood screening test. Several blood tests are under development. Any useful test must be validated with disease‐relevant blood reference panels. Study Design and Methods To generate blood reference materials, we infected four cynomolgus macaques with macaque‐adapted vCJD brain homogenates. Blood was collected throughout the preclinical and clinical phases of infection. In parallel, equivalent blood was collected from one uninfected macaque. For each blood collection, an aliquot was stored as whole blood and the remainder was separated into components. Aliquots of plasma from terminally ill macaques were assayed for the presence of PrPTSE with the protein misfolding cyclic amplification (PMCA) method. Infectivity of the macaque brain homogenate used to infect macaques was titrated in C57BL/6 and RIII J/S inbred wild‐type mice. Results We sampled blood 19 times from the inoculated monkeys at various stages of the disease over a period of 29 months, generating liters of vCJD‐infected macaque blood. vCJD was confirmed in all inoculated macaques. After PMCA, PrPTSE was detected in plasma from infected monkeys, but not from uninfected animals. Both mouse models were more sensitive to infection with macaque‐adapted vCJD agent than to primary human vCJD agent. Conclusion The macaque vCJD blood panels generated in this study provide a unique resource to support vCJD assay development and to characterize vCJD infectivity in blood.
ISSN:0041-1132
1537-2995
DOI:10.1111/trf.12841